Armand Abergel Selected Research

Hepatocellular Carcinoma (Hepatoma)

3/2024	Recipient age influences survival after liver transplant: Results of the French national cohort 2007-2017.
3/2023	Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.
11/2022	Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival.
1/2022	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.
4/2019	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
1/2019	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
11/2018	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
4/2017	[Regional differences in hospitalisations for complications of chronic hepatitis C in 2012].
1/2017	Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma.
6/2016	Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Armand Abergel Research Topics

Disease

37	Fibrosis (Cirrhosis) 02/2024 - 04/2002
19	Infections 12/2022 - 06/2002
13	Hepatocellular Carcinoma (Hepatoma) 03/2024 - 08/2002
10	Chronic Hepatitis C 01/2023 - 05/2002
7	Liver Diseases (Liver Disease) 11/2023 - 12/2006
7	Hepatitis C 01/2023 - 11/2003
6	Thrombophilia 02/2024 - 05/2003
6	Neoplasms (Cancer) 07/2021 - 05/2003
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 08/2009
4	Hypertension (High Blood Pressure) 01/2021 - 01/2018
3	Autoimmune Hepatitis 10/2023 - 01/2023
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2023 - 01/2021
3	Non-alcoholic Fatty Liver Disease 03/2023 - 02/2022
3	Thrombosis (Thrombus) 01/2022 - 07/2005
3	Hemorrhage 01/2022 - 01/2016
3	Pathologic Constriction (Stenosis) 01/2017 - 05/2014
2	Fatty Liver 03/2023 - 02/2022
2	Chronic Renal Insufficiency 01/2023 - 01/2018
2	Hydrothorax 01/2022 - 10/2017
2	Ascites 01/2022 - 01/2016
2	Hepatorenal Syndrome 01/2022 - 04/2002
2	Portal Hypertension 01/2022 - 01/2016
2	Disease Progression 01/2022 - 06/2018
2	Chronic Hepatitis B 01/2021 - 04/2019
2	Viremia 01/2018 - 02/2005
2	Hepatic Encephalopathy 04/2015 - 05/2014
2	Pancreatitis 09/2014 - 02/2013
2	Iron Overload 06/2009 - 12/2006
1	Massive Hepatic Necrosis 10/2023
1	Alcoholic Liver Diseases (Alcoholic Liver Disease) 11/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022
1	Hepatopulmonary Syndrome 01/2022
1	Brain Diseases (Brain Disorder) 01/2022
1	Renal Insufficiency (Renal Failure) 08/2021
1	Dehydration (Water Stress) 08/2021
1	Microsporidiosis 08/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Protein C Deficiency 09/2020
1	Obesity 12/2019
1	Occupational Stress 10/2019
1	End Stage Liver Disease 04/2019
1	Neutropenia 01/2019
1	Diabetes Complications 01/2019
1	Asthenia 01/2019

Drug/Important Bio-Agent (IBA)

11	Antiviral Agents (Antivirals)IBA 12/2022 - 10/2016
9	Ribavirin (Virazole)FDA LinkGeneric 04/2019 - 06/2002
9	InterferonsIBA 04/2019 - 06/2002
5	Thrombin FDA Link 02/2024 - 04/2017
5	Protease Inhibitors (Protease Inhibitor)IBA 04/2019 - 07/2014
5	SofosbuvirIBA 04/2019 - 12/2015
4	ThrombomodulinIBA 02/2024 - 04/2017
3	Transaminases (Aminotransferases)IBA 11/2023 - 02/2005
3	elbasvirIBA 01/2023 - 01/2018
3	grazoprevirIBA 01/2023 - 01/2018
3	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2010
3	BilirubinIBA 01/2022 - 04/2015
3	glecaprevir and pibrentasvirIBA 10/2020 - 01/2019
3	IronIBA 06/2018 - 12/2006
3	sofosbuvir drug combination ledipasvirIBA 01/2017 - 04/2015
2	AntithrombinsIBA 02/2024 - 09/2020
2	Protein CIBA 02/2024 - 04/2017
2	Biomarkers (Surrogate Marker)IBA 02/2022 - 10/2019
2	AlbuminsIBA 01/2022 - 10/2017
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2021 - 07/2005
2	SimeprevirIBA 04/2019 - 01/2017
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 01/2017
2	Oral ContraceptivesIBA 09/2018 - 05/2003
2	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 07/2014 - 07/2014
2	telaprevirIBA 07/2014 - 07/2014
2	Ethanol (Ethyl Alcohol)IBA 08/2002 - 08/2002
1	Prothrombin (Factor II)IBA 02/2024
1	Immunoglobulin G (IgG)IBA 10/2023
1	HDL CholesterolIBA 03/2023
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/2023
1	Opioid Analgesics (Opioids)IBA 01/2023
1	Cytidine Triphosphate (CTP)IBA 01/2023
1	AnticoagulantsIBA 01/2023
1	Indicators and Reagents (Reagents)IBA 02/2022
1	ABO Blood-Group SystemIBA 01/2022
1	Blood Group Antigens (Blood Groups)IBA 01/2022
1	fumagillinIBA 08/2021
1	Albendazole (Albenza)FDA Link 08/2021
1	Dihydrotachysterol (AT 10)IBA 07/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	P-300IBA 10/2020
1	Hormones (Hormone)IBA 12/2019
1	LeptinIBA 12/2019
1	GhrelinIBA 12/2019
1	glecaprevirIBA 01/2019
1	pibrentasvirIBA 01/2019

Therapy/Procedure

21	Liver Transplantation 11/2023 - 10/2012
17	Therapeutics 01/2023 - 06/2002
4	Stents 01/2017 - 05/2014
3	Transplantation 03/2023 - 02/2015
3	Drug Therapy (Chemotherapy) 01/2019 - 01/2017
3	Length of Stay 04/2017 - 09/2013
2	Aftercare (After-Treatment) 12/2022 - 01/2022
2	Transjugular Intrahepatic Portasystemic Shunt 01/2016 - 05/2014
1	Artificial Respiration (Mechanical Ventilation) 03/2024
1	Bariatric Surgery 03/2023